Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

University of Kansas claims new HSP 90 inhibitors

Sep. 27, 2010

Novartis reports on clinical development of LDE-225

Sep. 27, 2010

Interim phase I/II data suggest safety of everolimus in advanced HCC

Sep. 27, 2010

First selective Aurora kinase A inhibitors identified

Sep. 23, 2010

Peretinoin shows potential as first-line agent to prevent recurrence of HCC

Sep. 22, 2010

Hybrigenics reports phase IIa data on inecalcitol/docetaxel combination in prostate cancer

Sep. 21, 2010

Boehringer Ingelheim begins phase III afatinib trial in breast cancer

Sep. 21, 2010

Daiichi Sankyo identifies new inhibitors of HSP 90 ATPase activity

Sep. 21, 2010

Phase II trial begins for SG-2000 in ovarian cancer

Sep. 20, 2010

Urifer claims new heterocyclic compound for cancer therapy

Sep. 20, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...